F
Farida Souami
Researcher at Novartis
Publications - 8
Citations - 1512
Farida Souami is an academic researcher from Novartis. The author has contributed to research in topics: Letrozole & Cancer. The author has an hindex of 7, co-authored 8 publications receiving 1155 citations.
Papers
More filters
Journal ArticleDOI
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobagyi,Salomon M. Stemmer,Howard A. Burris,Yoon Sim Yap,Gabe S. Sonke,Shani Paluch-Shimon,Mario Campone,Kimberly L. Blackwell,Fabrice Andre,Eric P. Winer,Wolfgang Janni,Sunil Verma,Pierfranco Conte,Carlos L. Arteaga,David Cameron,Katarína Petráková,Lowell L. Hart,Cristian Villanueva,A. Chan,Erik Jakobsen,Arnd Nusch,Olga Burdaeva,Eva-Maria Grischke,Emilio Alba,Erik Wist,Norbert Marschner,Anne Favret,Denise A. Yardley,Thomas Bachelot,Ling-Ming Tseng,Sibel Blau,Fengjuan Xuan,Farida Souami,Michelle Miller,C. Germa,Samit Hirawat,Joyce O'Shaughnessy +36 more
TL;DR: Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those received placebo plus let rozole, with a higher rate of myelosuppression in the ribocIClib group.
Journal ArticleDOI
Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer
Nicoletta Colombo,Elzbieta Kutarska,Meletios A. Dimopoulos,Duk-Soo Bae,Izabella Rzepka-Górska,Mariusz Bidziński,Giovanni Scambia,Svend Aage Engelholm,Florence Joly,Dirk Weber,Mona El-Hashimy,Jingjin Li,Farida Souami,Patricia Wing,S.A. Engelholm,Aristotelis Bamias,Peter E. Schwartz +16 more
TL;DR: Patupilone did not demonstrate significant improvement in OS compared with the active control, PLD, and no new or unexpected serious AEs were identified.
Journal ArticleDOI
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
Joyce O'Shaughnessy,Katarína Petráková,Gabe S. Sonke,Pierfranco Conte,Carlos L. Arteaga,David Cameron,Lowell L. Hart,Cristian Villanueva,Erik Jakobsen,Joseph T. Beck,Deborah Lindquist,Farida Souami,S. Mondal,C. Germa,Gabriel N. Hortobagyi +14 more
TL;DR: Ribociclib plus letrozole improved progression-free survival vs placebo plus let rozole and was well tolerated in postmenopausal women with HR+, HER2− de novo advanced breast cancer.
Journal ArticleDOI
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
Gabe S. Sonke,Lowell L. Hart,Mario Campone,Frans L. G. Erdkamp,Wolfgang Janni,Sunil Verma,Cristian Villanueva,Erik Jakobsen,Emilio Alba,Erik Wist,Anne Favret,Thomas Bachelot,Roberto Hegg,Paul Wheatley-Price,Farida Souami,Santosh Sutradhar,Michelle Miller,C. Germa,Howard A. Burris +18 more
TL;DR: Addition of ribociclib to letrozole is a valid therapeutic option for elderly patients with HR+, HER2− advanced breast cancer in the first-line setting.
Journal ArticleDOI
LBA1 First-line ribociclib + letrozole in postmenopausal Asian women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from MONALEESA-2
Yoon Sim Yap,L-M Tseng,Kimberly L. Blackwell,David Cameron,S. Foo,Virote Sriuranpong,C.-S. Huang,T.-Y. Chao,Tae Yong Kim,S-C Chen,Kyung Hwa Jung,K.S. Lee,Joohyuk Sohn,Jihyeung Kim,M.-F. Hou,Y. Han,Farida Souami,S. Dhuria,M. Miller,Sunil Verma +19 more